US Patent

US12527771 — Viral inhibitors, the synthesis thereof, and intermediates thereto

Composition of Matter · Assigned to Takeda Pharmaceutical Co Ltd · Expires 2043-10-11 · 17y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects the composition of maribavir, a benzimidazole riboside used as an antiviral, and methods for providing it.

USPTO Abstract

The present disclosure discloses compositions comprising maribavir, methods of providing the same, and compositions providing intermediates useful in providing maribavir. Maribavir is a benzimidazole riboside and is useful as an antiviral.

Drugs covered by this patent

Patent Metadata

Patent number
US12527771
Jurisdiction
US
Classification
Composition of Matter
Expires
2043-10-11
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Takeda Pharmaceutical Co Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.